Diamonds and Dogs


Two drug stocks going in opposite directions. Biogen (BIIB) is up 3% after speaking at a conference in San Diego saying their Alzheimer's treatment showed a 30% benefit on cognitive decline for a subgroup of patients. In a second study called Engage, the benefit was 27%. This is key as Biogen previously scrapped both studies, saying they would fail. At least one analyst remains skeptical saying the new drug data is not that impressive and the old questions remain.

A depressing day for Sage Therapeutics (SAGE). The biotech is down 58% to a two year low after their Phase 3 trial for their depression drug SAGE-217 failed to perform better than a placebo in reducing depression after 15 days. Still, the company maintained that the drug still has some promise. 

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.